Education and Training
Menu

J. Nate Diehl, MD, PhD

Nate Diehl
Medical School: UNC - Chapel Hill Undergraduate: Clemson University

About Dr. Diehl

Nate Diehl is a resident in general surgery. He graduated from Clemson University before joining the medical scientist training program (MSTP) at the University of North Carolina - Chapel Hill to complete dual MD and PhD degrees. He hopes to pursue a career in academic surgery.

Education

2015 - 2023
MD - UNC-Chapel Hill

2017 - 2021
PhD - UNC-Chapel Hill (Genetics and Molecular Biology)

2011 - 2015
BS - Clemson University (Biochemistry)

Societies

2022 - present
Alpha Omega Alpha (AOA)

2018 - present
American Association of Cancer Research (AACR)

2016 - present
American Physician Scientist Association (APSA)

Awards

2023
George F. Sheldon Award for Excellence in Surgery
Department of Surgery, UNC-Chapel Hill

2023
AATS Member for a Day
American Association for Thoracic Surgery (AATS)

2023
MD/PhD Alexander Scholar
UNC-Chapel Hill School of Medicine

2022 
Alpha Omega Alpha (AOA)
UNC-Chapel Hill School of Medicine

2020
Best Scientific Poster, Postdoc-Faculty Research Day
UNC-Chapel Hill, Lineberger Comprehensive Cancer Center

2019
Best Scientific Talk, Department of Genetics Annual Scientific Retreat
UNC-Chapel Hill, Department of Genetics

2018
AACR Scholar-In-Training Award
American Association for Cancer Research (AACR)

2015
V. L. Tweedie Scholarship, Alpha Epsilon Delta Honor Society
Clemson University

2015
Outstanding Senior in Biochemistry
Clemson University

2015
Phi Kappa Phi Certificate of Merit
Clemson University

2015
Blue Key Academic and Leadership Award
Clemson University

2015
Jerome V. Reel Award of Academic Excellence, Omicron Delta Kappa Honor Society
Clemson University

2015
Summa Cum Laude, General and Departmental Honors
Clemson University

Research

2022 - 2023 
Division of Cardiothoracic Surgery, UNC-Chapel Hill 
Mentor: Jason Long, MD, MPH
Description: Investigated differences in 30-day morbidity and mortality following lung cancer resection in patients with or without serious mental illness (SMI).

2022 - 2023 
Division of Cardiothoracic Surgery, UNC-Chapel Hill 
Mentor: John Ikonomidis, MD
Description: Developed a method for extracellular vesicle (EV) extraction and quantification from human plasma samples with tunable resistive pulse sensing (TRPS) which was used to study EVs in patients with thoracic aortic aneurysms.

2017 - 2021 
Department of Pharmacology, UNC-Chapel Hill 
Mentor: Channing Der, PhD
Description: Identified underlying drivers of pancreatic adenocarcinoma (PDAC) by utilizing proteome and transcriptome analysis to inform the development of novel small-molecule cancer therapies.

2013 - 2015 
Department of Genetics and Biochemistry, Clemson University 
Mentor: Michael Sehorn, PhD
Description: Characterized the structure and function of multiple homologous recombination in vitro including RAD51-accessory factor BCCIP-beta and the human chromatin remodeler HELLS.

2010 - 2012 
Department of Cancer Biology, University of Pennsylvania 
Mentor: Sandra Ryeom, PhD
Description: Investigated the role of thrombospondin-1 (TSP1) in lung cancer chemotaxis and reactive oxygen species (ROS) formation using murine models.

Publications

Peer-reviewed Papers

  1. Diehl JN, Ray A, Collins LB, Peterson A, Alexander KC, Ikonomidis JS, and Akerman AW. (2023) A standardized method for plasma extracellular vesicle isolation and size distribution analysis. PLoS ONE Apr 28;18(4):e0284875
  2. Khoury AL, Diehl JN, Blumberg JM, Chang ASY, and Long JM. (2022) Microvascular Cutaneous Flap for Treatment of Complications of Black Esophagus and Complex Esophageal Reconstruction. JTCVS Tech. 2022 Dec 17;18:154-156
  3. Mucha B, Qie S, Bajpai S, Tarallo V, Diehl JN, Tedeschi F, Zhou G, Gao Z, Flashner S, Klein-Szanto AJ, Hibshoosh H, Masataka S, Chajewski OS, Majsterek I, Pytel D, Hatzoglou M, Der CJ, Nakagawa H, Bass AJ, Wong KK, Fuchs SY, Rustgi AK, Jankowsky E, and Diehl JA. (2022) Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation. Nat Commun. 13(1):6614.
  4. Javaid S, Schaefer A, Goodwin CM, Nguyen VV, Massey FL, Pierobon M, Gambrell-Sanders D, Waters AM, Lambert KN, Diehl JN, Hobbs AG, Wood KC, Petricoin EF, Der CJ, and Cox AD. (2022). Concurrent ERK Inhibition Blocks Farnesyltransferase Inhibitor-induced Epithelial-to-Mesenchymal Transition to Suppress the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 21(5):762-774.
  5. Huynh MV, Hobbs GA, Schaefer A, Pierobon M, Carey LM, Diehl JN, DeLiberty JM, Thurman RD, Cooke AR, Goodwin CM, Cook JH, Lin L, Petricoin EF, Campbell SL, Haigis KM, Simeone DM, Lyssiotis CA, Cox AD, and Der CJ. (2022) Functional and biological heterogeneity of KRASQ61 mutations. Sci Signal. 15(746):eabn2694.
  6. Diehl JN, Klomp JE, Snare KR, Blake DR, Hibshman PS, Stalnecker CA, Gilbert TSK, Baldelli E, Pierobon M, Herring LE, Papke B, Yang R, Hodge RG, Rashid NU, Petricoin EF, Graves LM, Cox AD, and Der CJ. (2021). The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. J Biol Chem. 297(5):101335.
  7. Diehl JN*, Hibshman PS*, Ozkan-Dagliyan O, Goodwin CM, Howard SV, Cox AD and Der CJ. (2021) Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Adv Cancer Res. 153:101-130. *indicates equal contribution
  8. Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KK, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, and Der CJ. (2021). Targeting p130Cas- and Microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 35(13):109291.
  9. Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Diehl JN, Stalnecker CA, Yin HH, Pierobon M, Runying R, Ryan MB, Li S, Peterson J, Gautam P, Petricoin EF, Counter CM, Cox AD, Wennerberg K, Bryant KL, and Der CJ. (2021). CHK1 Protects Oncogenic KRAS-expressing cells from DNA Damage and is a Target for Pancreatic Cancer Treatment. Cell Rep. 37(9):110060.
  10. Ozkan-Dagliyan I, Diehl JN, George SD, Schaefer A, Papke B, Klotz-Noack K, Waters AM, Goodwin CM, Gautam P, Pierobon M, Peng S, Gilbert TSK, Lin KH, Dagliyan O, Wennerberg K, Cox AD, Petricoin III EF, Tran NL, Bhagwat SV, Tiu RV, Peng SB, Herring LE, Graves LM, Sers C, Wood KC, and Der CJ. (2020) Vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS-mutant cancers. Cell Rep. 31:107764.
  11. Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge A, Stachler M, Liao J, Zhou J, Wu Z, Fahire A, de Klerk L, Derks S, Pierobon M, Hoadley K, Wang T, Church G, Wong K, Petricoin E, Cox AD, Lowy D, Der CJ, and Bass AJ. (2020) Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 10:288-305.
  12. Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson A, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Bryant KL, Esposito D, Campbell SL, Petricoin, III EF, Simanshu DK, Rudloff U, Cox AD and Der CJ. (2020) Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 10:104-123.
  13. Bryant KL, Stalnecker CA, Daniel Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda, V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode G, Chaika  NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin III EF, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, and Der CJ. (2019) ERK inhibition increases pancreatic cancer dependence on autophagy, Nat Med. 25:628-640.
  14. Kelso AA, Goodson SD, Watts LE, Ledford LL, Waldvogel SM, Diehl JN, Shah SB, Say AF, White JD and Sehorn MG. (2017) The β-isoform of BCCIP promotes ADP release from the RAD51 presynaptic filament and enhances homologous DNA pairing. Nucleic Acids Res. 45:711-725.
  15. Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL and Diehl JA. (2013) The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol. 33:4422-33.

Poster Presentations

  1. Diehl JN, Khoury AL, Brickey J, Mody GN, Haithcock BE, and Long JM. Serious mental illness prolongs hospital admission following thoracic surgery for lung cancer. 103rd Annual Meeting of the American Association for Thoracic Surgery (AATS), Los Angeles, CA. May 6-9th 2023.
  2. Khoury AL, Diehl JN, Long JM, Parodi F, and Mody GN. Long-term Outcome After Staged Approach to Emergent Aortoesophageal Fistula Repair. 103rd Annual Meeting of the American Association for Thoracic Surgery (AATS), Los Angeles, CA. May 6-9th 2023.
  3. Diehl JN, Klomp JE, Snare KR, Blake DR, Hibshman PS, Kaiser ZD, Gilbert TSK, Baldelli E, Pierobon M, Papke B, Yang R, Hodge RG, Rashid NU, Petricoin EF, Herring LE, Graves LM, Cox AD, & Der CJ. Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer. The Third RAS Initiative Symposium, Frederick, MD, USA. May 25th, 2021.
  4. Diehl JN, Klomp JE, Snare KR, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. Life without KRAS: profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities in pancreatic cancer. Postdoc-Faculty Research Day, virtual, November 6th, 2020.
  5. Diehl JN, Klomp JE, Snare KR, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. Life without KRAS: profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities in pancreatic cancer. 35th Annual National MD-PhD Student Conference, virtual, September 24-27th, 2020.
  6. Diehl JN, Klomp JE, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. Profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities of pancreatic cancer. Translation Medicine symposium, UNC-Chapel Hill, April 9th, 2019.
  7. Diehl JN, Klomp JE, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. Life without KRAS: profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities in pancreatic cancer. 30th Anniversary AACR Special Conference Convergence: Artificial Intelligence, Big Data and Prediction in Cancer, Newport, RI, October 14-17th, 2018.
  8. Diehl JN and Der CJ. The RAS homologous RHOA protein: Oncogene or tumor suppressor? John B. Graham Medical Student Research Day, UNC-Chapel Hill, November 30th, 2015.

Oral Presentations

  1. Diehl JN, Klomp JE, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. RASterization of the PDAC kinome. Annual UNC-Duke RAS Scientific Retreat, Emerald Isle, NC, May 20-22nd, 2019.
  2. Diehl JN, Klomp JE, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. A Tomato is a Fruit: Characterization of the KRAS-mutant kinome in pancreatic cancer. Department of Genetics Scientific Retreat, UNC-Chapel Hill, March 17th, 2019.
  3. Diehl JN, Klomp JE, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Hodge RG, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. Profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities of pancreatic cancer. Translation Medicine symposium, UNC-Chapel Hill, April 10th, 2018.
  4. Diehl JN, Blake DR, Gilbert TSK, Herring LE, Papke B, Vaseva AV, Yang R, Rashid N, Bryant KL, Graves LM, Cox AD and Der CJ. Kinome alterations in PDAC following KRAS loss or ERK inhibition. Annual UNC-Duke RAS Scientific Retreat, Emerald Isle, NC, September 11-13th, 2017.
  5. Diehl JN, Kelso AA, and Sehorn MG. Human chromatin remodeler HELLS is a DNA-dependent ATPase. ACC Meeting of the Minds Undergraduate Research Conference, Raleigh, NC, USA. April 12th, 2015.

Other Publications

  1. Diehl JN, Ray A, Collins LB, Peterson A, Alexander KC, Ikonomidis JS, and Akerman AW. (2022) Human sample processing and isolation of extracellular vesicles with size exclusion chromatography. https://protocols.io/view/human-sample-processing-and-isolation-of-extracell-cft9tnr6.html
  2. Diehl JN, Ray A, Collins LB, Peterson A, Alexander KC, Ikonomidis JS, and Akerman AW. (2022) Measurement of extracellular vesicles with tunable resistive pulse sensing. https://protocols.io/view/measurement-of-extracellular-vesicles-with-tunable-cfudtns6.html
  3. Podcast. Yeager, Calvin. Curioscity, Episode 92 – Non-mendelian genetics (w/ Nate Diehl!). Spotify, October 15, 2020. https://open.spotify.com/episode/0HDJnh4XSVpTDx53MWaPcn?si=a0Db-zfFST6t4rOzn9_EFQ
Share This Page:
Post Tweet